ClinicalTrials.gg
Not yet recruitingNCT06641388Updated Oct 15, 2024

A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects

A Phase 1 interventional study of Ebronucimab and Ebronucimab in Healthy Subjects (HS), sponsored by Akeso. Not yet recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Akeso · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This is a phase I clinical study to evaluate the pharmacokinetics (PK) similarity of single dose subcutaneous injection of Ebronucimab with different production processes in Chinese healthy male subjects.

Read the detailed description

This is a randomized, parallel controlled, phase I clinical study to evaluate the pharmacokinetics (PK) similarity of single dose subcutaneous injection of Ebronucimab with different production processes in Chinese healthy male subjects. This study consists of two parts: pre-trial part and formal-trial part, with a planned enrollment of approximately 180 healthy male participants from China.

02

Conditions studied

  • Healthy Subjects (HS)

Keywords

  • phase I
  • healthy subjects
03

In context

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Weight: 60\~80kg; (BMI) ≥ 19 and ≤ 26 kg /m2 for healthy Chinese male subjects.
  • Subjects fully understand the purpose, content, process, and potential adverse events of the trial, voluntarily participate in the trial, and sign an form before any trial procedure begins.
  • Low density lipoprotein cholesterol (LDL-C) levels ≥ 1.8mmol/L and ≤ 4.9mmol/L during screening.
  • Subjects are able to communicate well with the investigator and understand the requirements of the study.

Key Exclusion Criteria:

  • 12 months prior use of PCSK9 inhibitors treatment.
  • Allergic to the components of Ebronucimab and any monoclonal antibodies.
  • History of important organ transplantation (such as heart, lung, liver, kidney, etc.).
  • Abnormal vital signs during screening period and before randomization.
  • Drug abuse prior to screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Ebronucimab 150mg (after the change)

    Ebronucimab 150mg Single subcutaneous injection into the abdomen.

    Drug: Ebronucimab

  • Experimental
    Ebronucimab 150mg (before the change)

    Ebronucimab 150mg Single subcutaneous injection into the abdomen.

    Drug: Ebronucimab

Interventions

06

What researchers measure

Primary outcomes

  1. Area under curve (AUC)

    Assess the AUC of Ebronucimab

    Time frame: Baseline till last follow-up visit( up to day 43 or day 57)

  2. Maximum (peak) plasma concentration (Cmax)

    Assess the Cmax of Ebronucimab

    Time frame: Baseline till last follow-up visit( up to day 43 or day 57)

  3. Incidence of adverse events(AE)

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: From the time of signing the informed consent form till last follow-up visit( up to day 43 or day 57)

Secondary outcomes

  1. Free protein convertase of proprotein convertase subtilisin/kexin type 9 (PCSK-9)

    Concentration and percentage change from baseline of free protein convertase PCSK-9

    Time frame: Baseline till last follow-up visit( up to day 43)

  2. Immunogenicity index

    Number and percentage of subjects with detectable anti drug antibodies (ADA) and neutralizing antibodies (Nab) after treatment.

    Time frame: Day 1 and Day 57

  3. PCSK-9 concentration

    Percentage change in PCSK-9 concentration compared to baseline

    Time frame: Day 1 and Day 57

  4. Serum Low-density lipoprotein Cholesterol (LDL-C) concentration

    The change value and percentage of serum LDL-C concentration compared to baseline

    Time frame: Day 1 and Day 57

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2024; primary completion for Apr 2025, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2024
First posted
Oct 15, 2024
StartEst.
Nov 4, 2024
Primary completionEst.
Apr 30, 2025
CompletionEst.
Jun 17, 2025
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06641388
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Nov 4, 2024 (estimated)
Primary completion
Apr 30, 2025 (estimated)
Completion
Jun 17, 2025 (estimated)
Last update
Oct 15, 2024

Study contacts

Guoqin Wang
Contact
global.trials@akesobio.com
+86 (0760) 8987 3999

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ebronucimab

Start the discussion